Compare Charles River Laboratories Intl. Inc (CRL) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs HubSpot Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $232.3 (market cap $11.14B), while HubSpot Inc trades at $219.84 (market cap $10.73B). The key difference: Charles River Laboratories Intl. Inc and HubSpot Inc are close in size by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals.
| CRL | HUBS | |
|---|---|---|
Market Cap | $11.14B | $10.73B |
Sector | Health | Technology |
52-Week High | $233.60 | $560.90 |
52-Week Low | $145.57 | $170.39 |
Enterprise Value | $14.00B | $9.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
HubSpot (HUBS) trades at $217.59, up 4.87% with a bullish technical signal. The stock shows strong revenue growth, reaching $3.13B in 2025, and has beaten earnings estimates for three consecutive quarters. Analyst sentiment is overwhelmingly positive with an 80.85% buy rating and a consensus price target of $273.53. Recent news highlights AI-driven expansion and customer growth, with the company hosting an Analyst Day in September 2026.
The outlook for HUBS is favorable due to robust fundamentals and AI integration, but risks include high valuation multiples and competitive pressures. Upside potential exists if earnings growth continues, though investors should monitor margin expansion and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
